Cardiovascular and microvascular outcomes according to vitamin D level and genetic variants among individuals with prediabetes: a prospective study.

Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2003-

Prediabetic State*/genetics ; Diabetic Nephropathies* ; Myocardial Infarction*/genetics ; Stroke* ; Vitamin D Deficiency*; Adult ; Humans ; Prospective Studies ; Vitamin D

Background: Whether serum vitamin D mediate vascular diseases in prediabetic populations remains unclear. This study aimed to determine the associations between circulating 25-hydroxyvitamin D [25(OH)D] levels and vitamin D receptor (VDR) polymorphisms with the risk of macrovascular complications, including myocardial infarction and stroke, and microvascular complications such as diabetic nephropathy and retinopathy, among adults with prediabetes.
Methods: Participants with prediabetes in UK Biobank were included (N = 56,387). Multivariable dose-response and Cox proportion models were used to explore the relationship of serum 25(OH)D status and the risks of vascular complications. The interaction of VDR polymorphisms with serum 25(OH)D level on risks of vascular events was also assessed.
Results: During a median follow-up of 12 years, higher levels of 25(OH)D were significantly and nonlinearly associated with a lower risk of macrovascular diseases among prediabetic individuals. The adjusted hazard ratios (95% confidential interval) of serum 25(OH)D levels of ≥ 75.0 nmol/L versus < 25 nmol/L were 0.75 (0.63-0.88) for myocardial infarction, 0.74 (0.55-1.00) for stroke, 1.02 (0.60-1.74) for diabetic nephropathy, and 1.30 (0.92-1.84) for diabetic retinopathy, respectively. The rs2228570 (FokI) polymorphisms significantly interacted with 25(OH)D on incident myocardial infarction (P-interaction = 0.042) and stroke (P-interaction = 0.033). The individuals with serum 25(OH)D level of 50.0-74.9 nmol/L and rs2228570 (FokI) homozygotes had the lowest risks of vascular complications.
Conclusions: Lower serum 25(OH)D levels are significantly and nonlinearly associated with an increased risk of cardiocerebrovascular diseases in prediabetic individuals, with VDR polymorphisms of rs2228570 (FokI) modify such associations. Monitoring a safe 25(OH)D concentration is suggested to prevent the vascular complications for prediabetes.
(© 2023. BioMed Central Ltd., part of Springer Nature.)

Huang JY, Tse YK, Li HL, Chen C, Zhao CT, Liu MY, et al. Prediabetes is associated with increased risk of heart failure among patients with atrial fibrillation. Diabetes Care. 2023;46(1):190–6.
Choi G, Yoon H, Choi HH, Ha KH, Kim DJ. Association of prediabetes with death and diabetic complications in older adults: the pros and cons of active screening for prediabetes. Age Ageing. 2022. https://doi.org/10.1093/ageing/afac116 . (PMID: 10.1093/ageing/afac116)
Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, Maalmi H, Rathmann W, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022;65(2):275–85.
Kirthi V, Nderitu P, Alam U, Evans JR, Nevitt S, Malik RA, et al. The prevalence of retinopathy in prediabetes: a systematic review. Surv Ophthalmol. 2022;67(5):1332–45.
Hopper I, Billah B, Skiba M, Krum H. Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil. 2011;18(6):813–23.
Chen X, Wan Z, Geng T, Zhu K, Li R, Lu Q, et al. Vitamin D status, vitamin D receptor polymorphisms, and risk of microvascular complications among individuals with type 2 diabetes: a prospective study. Diabetes Care. 2022;46(2):270.
Emerging Risk Factors Collaboration EPIC-CVD, Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. Lancet Diabetes Endocrinol. 2021;9(12):837–46.
Wan Z, Guo J, Pan A, Chen C, Liu L, Liu G. Association of serum 25-Hydroxyvitamin D concentrations with all-cause and cause-specific mortality among individuals with diabetes. Diabetes Care. 2021;44(2):350–7.
Al MI, Quyyumi AA. Vitamin D and cardiovascular disease: controversy unresolved. J Am Coll Cardiol. 2017;70(1):89–100.
Herrmann M, Sullivan DR, Veillard AS, McCorquodale T, Straub IR, Scott R, et al. Serum 25-hydroxyvitamin D: a predictor of macrovascular and microvascular complications in patients with type 2 diabetes. Diabetes Care. 2015;38(3):521–8.
Renke G, Starling-Soares B, Baesso T, Petronio R, Aguiar D, Paes R. Effects of vitamin D on cardiovascular risk and oxidative stress. Nutrients. 2023;15(3):769.
Sheng L, Turner AG, Barratt K, Kremer R, Morris HA, Callen DF, et al. Mammary-specific ablation of Cyp24a1 inhibits development, reduces proliferation and increases sensitivity to vitamin D. J Steroid Biochem Mol Biol. 2019;189:240–7.
Reddy GS, Muralidharan KR, Okamura WH, Tserng KY, McLane JA. Metabolism of 1alpha,25-dihydroxyvitamin D(3) and its C-3 epimer 1alpha,25-dihydroxy-3-epi-vitamin D(3) in neonatal human keratinocytes. Steroids. 2001;66(3–5):441–50.
Berretta M, Quagliariello V, Bignucolo A, Facchini S, Maurea N, Di Francia R, et al. The Multiple effects of vitamin D against chronic diseases: from reduction of lipid peroxidation to updated evidence from clinical studies. Antioxidants. 2022;11(6):1090.
Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA. 2012;308(18):1898–905.
Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for cardiovascular research. Eur Heart J. 2019;40(14):1158–66.
Vistisen D, Witte DR, Brunner EJ, Kivimaki M, Tabak A, Jorgensen ME, et al. Risk of Cardiovascular disease and death in individuals with prediabetes defined by different criteria: the Whitehall II study. Diabetes Care. 2018;41(4):899–906.
Wang M, Zhou T, Li X, Ma H, Liang Z, Fonseca VA, et al. Baseline vitamin D status, sleep patterns, and the risk of incident type 2 diabetes in data from the Uk biobank study. Diabetes Care. 2020;43(11):2776–84.
Zhang P, Guo D, Xu B, Huang C, Yang S, Wang W, et al. Association of Serum 25-Hydroxyvitamin D With cardiovascular outcomes and all-cause mortality in individuals with prediabetes and diabetes: results from the uk biobank prospective cohort study. Diabetes Care. 2022;45(5):1219–29.
Lu Q, Wan Z, Guo J, Liu L, Pan A, Liu G. Association between serum 25-hydroxyvitamin D concentrations and mortality among adults with prediabetes. J Clin Endocrinol Metab. 2021;106(10):e4039–48.
Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52(5):828–32.
Zhou A, Selvanayagam JB, Hypponen E. Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk. Eur Heart J. 2022;43(18):1731–9.
Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38.
Mitri J, Pittas AG. Vitamin D and diabetes. Endocrinol Metab Clin North Am. 2014;43(1):205–32.
Norman PE, Powell JT. Vitamin D and cardiovascular disease. Circ Res. 2014;114(2):379–93.
de la Guia-Galipienso F, Martinez-Ferran M, Vallecillo N, Lavie CJ, Sanchis-Gomar F, Pareja-Galeano H. Vitamin D and cardiovascular health. Clin Nutr. 2021;40(5):2946–57.
Zweck E, Scheiber D, Schultheiss HP, Kuss O, Kelm M, Roden M, et al. Impaired myocardial mitochondrial respiration in humans with prediabetes: a footprint of prediabetic cardiomyopathy. Circulation. 2022;146(15):1189–91.
Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20(1):150.
Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13(5):336–59.
Santos-Gallego CG, Requena-Ibanez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, et al. Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction. Circ Cardiovasc Imaging. 2023;16(4): e15298.
Cojic M, Kocic R, Klisic A, Kocic G. The effects of vitamin D supplementation on metabolic and oxidative stress markers in patients with type 2 diabetes: A 6-month follow up randomized controlled study. Front Endocrinol. 2021;12: 610893.
Silva L, de Queiroz N, de Melo F, Abrahao NJ, Janau LC, de Souza NN, et al. Improvement in cardiovascular autonomic neuropathy after high-dose vitamin D supplementation in patients with type 1 diabetes. Front Endocrinol. 2020;11: 605681.
Jenkins D, Spence JD, Giovannucci EL, Kim YI, Josse RG, Vieth R, et al. Supplemental vitamins and minerals for cardiovascular disease prevention and treatment: JACC focus seminar. J Am Coll Cardiol. 2021;77(4):423–36.
Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. Vitamin D, calcium supplements, and implications for cardiovascular health: JACC focus seminar. J Am Coll Cardiol. 2021;77(4):437–49.
de Boer IH, Zelnick LR, Ruzinski J, Friedenberg G, Duszlak J, Bubes VY, et al. Effect of vitamin D and Omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2019;322(19):1899–909.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33–44.
Zhang Y, Fang F, Tang J, Jia L, Feng Y, Xu P, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ. 2019;366: l4673.
Scragg R, Stewart AW, Waayer D, Lawes C, Toop L, Sluyter J, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiol. 2017;2(6):608–16.
Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022;376: e66452.
Albert CM, Cook NR, Pester J, Moorthy MV, Ridge C, Danik JS, et al. Effect of marine omega-3 fatty acid and vitamin D supplementation on incident atrial fibrillation: a randomized clinical trial. JAMA. 2021;325(11):1061–73.
Neale RE, Baxter C, Romero BD, McLeod D, English DR, Armstrong BK, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol. 2022;10(2):120–8.
Abu EMM, Hassanein SI, Gad MZ. Genetic variation in vitamin D receptor gene (Fok1:rs2228570) is associated with risk of coronary artery disease. Biomarkers. 2016;21(1):68–72.
Jia J, Tang Y, Shen C, Zhang N, Ding H, Zhan Y. Vitamin D receptor polymorphism rs2228570 is significantly associated with risk of dyslipidemia and serum LDL levels in Chinese Han population. Lipids Health Dis. 2018;17(1):193.
Earthman CP, Beckman LM, Masodkar K, Sibley SD. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes. 2012;36(3):387–96.
Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690–3.
Kahwati LC, LeBlanc E, Weber RP, Giger K, Clark R, Suvada K, et al. Screening for vitamin D deficiency in adults. JAMA. 2021;325(14):1443.
Gregg EW, Moin T. New USPSTF Recommendations for screening for prediabetes and type 2 diabetes: an opportunity to create national momentum. JAMA. 2021;326(8):701–3.
Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for prediabetes and type 2 diabetes: US preventive services task force recommendation statement. JAMA. 2021;326(8):736–43.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2022;65(12):1925–66.
Galior K, Ketha H, Grebe S, Singh RJ. 10 years of 25-hydroxyvitamin-D testing by LC-MS/MS-trends in vitamin-D deficiency and sufficiency. Bone Rep. 2018;8:268–73.
Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.
Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, et al. Clinical review: Effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3551–60.

Keywords: Complications; Prediabetes; Serum 25(OH) D; UK biobank; rs2228570

1406-16-2 (Vitamin D)

Date Created: 20231016 Date Completed: 20231023 Latest Revision: 20231122

20240628

PMC10577927

10.1186/s12967-023-04557-x

37845735